Leadership Change in Tecan's Partnering Business Division
The Tecan Group, a prominent name in laboratory automation, has announced a significant change in its Partnering Business division. Ralf Griebel, who has played an instrumental role in the division since his appointment as Head in April 2020, will be leaving the company to explore new opportunities. His contributions have been vital in steering Tecan's Partnering Business towards growth and innovation.
Recognizing Contributions
The Board of Directors and CEO Monica Manotas expressed their gratitude to Ralf Griebel for his dedication and impactful work during his tenure. His efforts have not only developed the business but have also set a robust foundation for future advancements within Tecan.
Interim Leadership Under Monica Manotas
With Griebel's departure, CEO Monica Manotas will take on the role of interim leader for the Partnering Business division. This transitional phase offers her the chance to deepen her involvement with the team and the ongoing projects. Monica's leadership is expected to ensure continuity and drive further progress while the company explores permanent leadership options.
The Role of the Partnering Business Division
Tecan's Partnering Business division is central to its strategy, focusing on fostering innovative collaborations with various companies worldwide. This initiative has been pivotal in enhancing Tecan's offerings and its reputation as a leading provider of laboratory solutions.
Company Overview of Tecan
Founded in Switzerland in 1980, Tecan has positioned itself as a leader in lab automation. With more than 3,000 employees and a global presence, Tecan is committed to elevating healthcare through innovative solutions. The company designs and manufactures OEM instruments, components, and medical devices, distributing these products through a network of partners across over 70 countries.
Recent Performance Highlights
In a recent financial report, Tecan demonstrated remarkable growth, achieving CHF 934 million in sales, equivalent to approximately USD 1,062 million and EUR 984 million. This performance underscores Tecan's effective strategy and solid market position, ensuring it continues to propel healthcare innovation.
Future Outlook
Looking ahead, Tecan remains focused on enhancing its capabilities within the Partnering Business division. The leadership change represents not just a transition but an opportunity to further align the division with Tecan's strategic objectives and goals. As the industry evolves, Tecan is poised to adapt and thrive in its mission to improve lives through health technology.
Contact Information for Further Inquiries
For more information about Tecan and its offerings, Martin Brändle, Senior Vice President of Corporate Communications & IR, is available. Interested parties can reach out via phone at +41 (0) 44 922 84 30 or send a fax to +41 (0) 44 922 88 89. For inquiries via email, contact investor@tecan.com. Visit Tecan's website at www.tecan.com for additional resources.
Frequently Asked Questions
What prompted the leadership change in Tecan?
The leadership change was initiated by Ralf Griebel's decision to pursue new opportunities, necessitating a leadership transition.
Who is handling the interim leadership of the division?
CEO Monica Manotas will take on the interim leadership role for the Partnering Business division following Ralf Griebel's departure.
How has Tecan performed recently in terms of sales?
Recently, Tecan reported sales of CHF 934 million, showcasing substantial growth and stability in the market.
What is the primary focus of Tecan's Partnering Business division?
The Partnering Business division focuses on innovative collaborations to enhance Tecan's laboratory solutions and offerings globally.
Where can I find more information about Tecan?
For additional information, you can visit Tecan's official website at www.tecan.com or contact their Corporate Communications department directly.
